In a new study, researchers from the University of California-Los Angeles studied tumor response and overall survival following the administration of a new treatment among patients with advanced melanoma. This agent, called pembrolizumab, is an antibody that blocks PD-1, a protein which prevents the body's immune system from attacking the cancer.
The researchers tested pembrolizumab on more than 650 patients in North America, Europe and Australia. They looked at tumor response before and after treatment and found that the lesions were smaller in about one third of patients. In patients who responded to the treatment, seventy-five percent maintained the response at one or two years.
Source: Thenewsmarket
GMT 11:00 2018 Tuesday ,20 November
Iraqi children continue to suffer conflict, inequality in last 7 yearsGMT 18:15 2018 Wednesday ,05 September
Shaikh Khalid bin Hamad receives Bahraini researcherGMT 22:05 2018 Monday ,15 January
DERASAT ranked among top five Arab research centresGMT 04:26 2018 Tuesday ,09 January
IES honored with Meritorious AIP Best Performing School Award 2017GMT 22:21 2018 Monday ,01 January
Works minister receives researcherGMT 00:07 2017 Tuesday ,26 December
Study on thermal insulation presentedGMT 10:31 2017 Wednesday ,20 December
‘Turkish Corner’ to help students, researchers understand Turkish cultureGMT 08:35 2017 Sunday ,19 November
AGU showcases international research in medical computer simulationMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor